# Gufic BioSciences share price today (Gufic BioSciences Ltd, NSE: GUFICBIO)

> Gufic BioSciences share price today: ₹416.50 at the NSE close on 3 November 2026, up 28.0% in a year. Gufic BioSciences (NSE: GUFICBIO) is worth ₹4,172 crore, trades at a P/E of 56.8 and has closed between ₹279.15 and ₹444.90 over the past 52 weeks. > Gufic BioSciences Ltd's share price, valuation and earnings point in different directions. The next one or two quarters should make it clearer. GUFICBIO · Pharma - Formulators · data as of 3 November 2026. Page: https://www.sectoralpha.in/stocks/gufic-biosciences-ltd

Sector Alpha also publishes a daily newsletter that explains one Indian stock at a time: https://newsletter.sectoralpha.in/?utm_source=sectoralpha&utm_medium=ai_text&utm_campaign=llms

## Key numbers

- Business trend: Mixed, from the last 12 quarters
- Price: ₹416.50 (+28.0% in a year)
- P/E: 56.8× (higher than 63% of the last 2.4 years)
- Revenue (Jun 2026): ₹261 Cr (+16.5% on a year ago)
- Profit (Jun 2026): ₹22.0 Cr (+69.2% on a year ago)
- Operating margin: 18.0% (+3.0 points on a year ago)
- ROCE: 12%, FY26
- ROIC: 9.8%, against a 12.0% cost of capital: −2.2 points

The main question: the share price moved +28.0% in a year while yearly earnings per share moved −7.9%. The difference came from the market paying a higher multiple. ## What is the Gufic BioSciences share price today? Gufic BioSciences Ltd's share price was ₹416.50 at the close on 3 November 2026. It has been rising for 18 weeks. That is 10.4% above its average price over the last 200 trading days. In the last 52 weeks it traded between ₹279 and ₹445, and at that close it sat 83% of the way up from that low. Over the past 13 weeks it has done better than the NIFTY 500, and it has stayed ahead for 31 weeks in a row. Over the last 11 years the share price moved +837% while the NIFTY 500 moved +251%, so it is ahead of the index over that whole period. The chart above shows the 13-week comparison for every week. This page treats a rise as over when the price closes below its 200-day average on two Fridays in a row. ## What changed at Gufic BioSciences this quarter? 1. Revenue up on a year earlier for 7 quarters in a row In the June 2026 quarter revenue was ₹261 crore, +16.5% on a year earlier. Why: Revenue rose because the international business started earning fees and licensing income and got its first overseas contract manufacturing orders. Making GLP-1 products for Hetero also began. Next results: check whether the Indore plant gets used enough to reach the stated range by the end of the year. From the earnings call on 17 Aug 2026. 3. Highest quarterly revenue in 12 quarters Revenue of ₹261 crore in the June 2026 quarter is the highest of the last 12 quarters. Why: Revenue reached a 12-quarter high because the international business started earning fees and licensing income and got its first overseas contract manufacturing orders. Making GLP-1 products for Hetero also began. From the earnings call on 17 Aug 2026. ## What are Gufic BioSciences' latest quarterly results? For April to June 2026 (the quarter ended 30 June 2026), Gufic BioSciences reported revenue of ₹261 crore, up 16.5% from ₹224 crore a year earlier, and a profit of ₹22.0 crore, up 69.2% from ₹13.0 crore. ### Gufic BioSciences results: April to June 2026 against a year earlier

| Measure | April to June 2026 | April to June 2025 | Change |
| --- | --- | --- | --- |
| Revenue | ₹261 crore | ₹224 crore | +16.5% |
| Profit | ₹22.0 crore | ₹13.0 crore | +69.2% |
| Earnings per share | ₹2.22 | ₹1.30 | +70.8% |
| Operating margin | 18.0% | 15.0% | +3.0 points |

The next results, for July to September 2026, are due by 14 November 2026: listed companies must publish quarterly results within 45 days of the quarter's end (60 days for the January to March quarter). Gufic BioSciences' management discussed these results on a call held on 17 August 2026; what it said is further down this page. (From the company's reported quarterly results (quarter ended 30 June 2026). Revenue and profit in ₹ crore.)

## What is the Gufic BioSciences share price history? Gufic BioSciences closed at ₹416.50 on 3 November 2026, up 28.0% from ₹325.40 a year earlier (31 October 2025) and up 121.8% over five years. Its highest weekly close since March 2016 was ₹485.45 on 8 November 2024. ### Gufic BioSciences share price: then and now

| When | Close | Change to 3 Nov 2026 |
| --- | --- | --- |
| 1 week ago · 23 Oct 2026 | ₹392.60 | +6.1% |
| 1 month ago · 1 Oct 2026 | ₹418.20 | −0.4% |
| 6 months ago · 30 Apr 2026 | ₹284.60 | +46.3% |
| 1 year ago · 31 Oct 2025 | ₹325.40 | +28.0% |
| 3 years ago · 3 Nov 2023 | ₹270.60 | +53.9% |
| 5 years ago · 4 Nov 2021 | ₹187.80 | +121.8% |
| 10 years ago · 4 Nov 2016 | ₹48.15 | +765.0% |
| Earliest weekly close in our records · 11 Mar 2016 | ₹44.45 | +837.0% |
| Highest weekly close since March 2016 · 8 Nov 2024 | ₹485.45 | −14.2% |
| Lowest weekly close since March 2016 · 14 Oct 2016 | ₹35.70 | +1,066.7% |
| 52-week high (weekly close) · 4 Sep 2026 | ₹444.90 | −6.4% |
| 52-week low (weekly close) · 6 Mar 2026 | ₹279.15 | +49.2% |

Weekly closing prices. Each change is the move from that price to the 3 Nov 2026 close. A day's intraday high or low can go beyond these weekly closes. (563 weekly closes from 11 March 2016 to 3 November 2026.)

## What is the latest news on Gufic BioSciences? 3 Nov 2026: Gufic BioSciences closed at ₹416.50, up 6.1% on the week and down 0.4% on the month. 28 Aug 2026: ex-date for a dividend of ₹0.10 a share. ### Earlier

- 17 Aug 2026: Gufic BioSciences held its results call for April to June 2026. Management guided: Company growth of 15-20% on a year earlier for FY27; 15% described as the bare minimum. - Results for April to June 2026: Revenue up 16.5% and profit up 69.2% on a year earlier. ## What dividend does Gufic BioSciences pay? Gufic BioSciences paid ₹0.10 a share in regular dividends in the 12 months to 4 November 2026 (1 payment), a yield of 0.02% at the ₹416.50 close on 3 November 2026. The last was a dividend of ₹0.10 a share, ex-date 28 August 2026. ### Gufic BioSciences dividends since 1 April 2021

| Ex-date | Dividend per share | Type |
| --- | --- | --- |
| 28 Aug 2026 | ₹0.10 | Dividend |
| 22 Sep 2025 | ₹0.10 | Dividend |
| 17 Sep 2024 | ₹0.10 | Dividend |
| 21 Sep 2023 | ₹0.10 | Dividend |
| 24 Aug 2022 | ₹0.10 | Dividend |
| 9 Sep 2021 | ₹0.10 | Dividend |

Amounts as the company declared them on the NSE. A dividend goes to whoever owns the shares before the ex-date. The record date is the same day as the ex-date for every payment here. 5 of 5 Of the last 5 financial years, years with an NSE dividend record

Yes. Gufic BioSciences Ltd paid out 2% of its profit as dividends in FY26, and it paid a dividend in each of its last 3 reported years. (From the NSE corporate-actions record, read 4 November 2026.)

## What did Gufic BioSciences management say on the latest results call? On the call for April to June 2026, held on 17 August 2026, Gufic BioSciences' management guided: Company growth of 15-20% on a year earlier for FY27; 15% described as the bare minimum. > “Our revenues would be purely as a CMO. Again, I am reiterating that we are not going to do any front-end, neither in India nor abroad.”
> Pranav Choksi, on the call for April to June 2026

### What management guided

- Indore utilization planned at 40-45% by FY27 year-end; EU certification feedback expected in 1-2 months, new depot/microsphere and lipid-antifungal lines planned during FY27, with leverage by mid-FY27-28. - GLP-1 CMO activity expected to pick up in Q2 and gain momentum in Q3; end-year objective roughly 30% domestic and 70% international. - Current-infrastructure revenue potential of ₹1,600-1,800 crore without capital spending, subject to current product mix and legacy realizations. - Indore product mix over the next three years planned at 20% liquids, 50-60% lyophilization and 20-30% complex injectables. Management’s own plans and goals, from our notes of the call. A plan is not a result. Source: [the call transcript](https://files.tijorifinance.com/insight/india/1099/Conference Call/CC-Aug26.pdf). (From the call for April to June 2026, 17 August 2026.)

## What to watch in Gufic BioSciences' next results? When Gufic BioSciences reports July to September 2026, these are the 4 checks that show whether the story is still on course. First: Indore utilization to reach the stated year-end range; check depot, microsphere and lipid-antifungal readiness plus export mix. - What to check (from the call)
- Indore utilization to reach the stated year-end range; check depot, microsphere and lipid-antifungal readiness plus export mix. - Indore EU certificate feedback in the indicated window; check corrective-action closure and resulting regulated-market margin contribution. - GLP-1 CMO traction to build through the next two quarters; check Hetero approvals, partner demand and geographic production mix. - International fee income and Australian/North American arrangements to convert into recurring supply; check whether commercial revenue broadens. ## Which stock lists is Gufic BioSciences on? Gufic BioSciences is on 2 of our India lists: Momentum stocks and Pharma stocks. - [Momentum stocks Market cap cr: 4177.5848144118](https://www.sectoralpha.in/momentum-stocks-india)
- [Pharma stocks Market value (₹ crore): 4177.5848144118](https://www.sectoralpha.in/sectors/pharma-stocks-india)

## Is Gufic BioSciences profitable? Gufic BioSciences Ltd earned ₹22.0 Cr of net profit in the Jun 2026 quarter, +69.2% on the same quarter a year earlier. That is the 2nd quarter in a row of profit growth. Full-year FY26 profit was ₹64.0 Cr. Over 2 years profit has grown −13.7% a year on average. That is 8.4% of the quarter's revenue. The same quarter a year earlier earned ₹13.0 Cr. For the full year, FY26 profit was ₹64.0 Cr (−8.6% on the year before). Why profit moved: revenue changed +16.5% on a year earlier and the margin moved +3.0 percentage points. Most of the change came from keeping more of each sale. On average over the last four quarters, profit changed +46.2% and revenue +16.7%. Profit is growing faster than sales: fixed costs are spread over more sales, so each extra rupee of revenue adds more to profit. ## How much revenue does Gufic BioSciences make, and is it growing? Gufic BioSciences Ltd reported ₹261 Cr of revenue in the Jun 2026 quarter, +16.5% on the same quarter a year earlier. That is the 7th quarter in a row with growth on the year before. Over 2 years it has grown 8.2% a year on average. The last full year, FY26, came in at ₹944 Cr. The last four reported quarters add to ₹981 Cr. FY26 revenue was ₹944 Cr, +15.1% on the year before. Recent pace: the last four quarters grew +16.7% on average, against 8.2% a year over the longer run, so this year is growing faster than its own long-run rate. Is growth speeding up? Revenue over the last 12 months grew +16.6%, against +9.7% a year over the last 8 quarters (accelerating); profit over the last 12 months grew +17.7%, against −7.9% a year (accelerating). ## How much of every ₹100 of sales does Gufic BioSciences keep? Gufic BioSciences Ltd's operating margin was 18.0% in the Jun 2026 quarter, 3.0 percentage points higher than the same quarter a year ago. Across 3 years it has been between 16.0% and 19.0%. The latest quarter is within that range. Why the margin moved: operating margin changed +3.0 percentage points on the year while gross margin changed +1.0 points. So the gain came mostly from costs below the gross margin, such as staff and overheads, measured against sales. ## Is Gufic BioSciences' profit turning into cash? Over the last 3 years, 73% of Gufic BioSciences Ltd's reported profit came in as cash from its operations, so most of the profit is real cash. In FY26 it brought in ₹45.0 Cr of operating cash against ₹64.0 Cr of profit. After ₹16.0 Cr of spending on assets, ₹29.0 Cr was left over as free cash. Cash-flow figures here are yearly, because quarterly cash statements are not published, so this section changes once a year. Why 73% of profit came in as cash: the cash cycle got 43 days longer between FY24 and FY26, so more of each rupee of profit waits in the business before it arrives. What to look at next: less of the profit turns into cash than it should, and the cash cycle is 43 days longer. The next section looks at where the cash is stuck. ## Where does Gufic BioSciences' cash go? Gufic BioSciences Ltd's cash cycle, the days between paying suppliers and getting paid by customers, was 224 days in FY26, up from 181 days in FY24. It spent ₹99.0 Cr on assets over the last 2 years. Customers take 115 days to pay, and stock sits for 281 days on average. At FY26 sales of ₹944 Cr, each day of that cycle ties up about ₹2.6 Cr, so roughly ₹579 Cr is tied up in the business at any time. FY26: customers took 115 days to pay and stock sat for 281 days, about 9.2 months of sales sitting as stock, for a full cycle of 224 days, longer than FY24's 181. The full loop: cash goes out to suppliers and production on day 0. Stock sits for 281 days. Customers pay about 115 days after that. Suppliers are paid at 172 days. Together that makes the 224-day cycle. Spending on assets: ₹99.0 Cr over the last 2 years, against ₹52.0 Cr of depreciation (the yearly wear and tear on existing assets). So it is building well beyond replacing what wears out. Work still in progress is ₹22.0 Cr (FY26): assets paid for that are not earning yet. In short: cash is getting stuck in the daily cycle, so watch the cycle more than the profit. ## What is Gufic BioSciences' P/E ratio, and how does it compare with its own history? Gufic BioSciences Ltd's P/E is 56.8×, in the middle of its own history: higher than 63% of past readings. Its usual P/E (the middle reading) is 55.3×, over 2.4 years of weekly prices. This compares the share price with the company’s own past. It does not say what the business is worth. Why the multiple is where it is: over the past year earnings per share moved −7.9% while the price moved +28.0%. The price did better than earnings, which pushed the multiple up within its own range. In short: the multiple is about average against its own past, so the earnings trend underneath matters more than the multiple. ## Is the Gufic BioSciences business getting better or worse? Gufic BioSciences Ltd's business is giving mixed signals. There is no clear direction across the growth lines, with ROCE rising at 16.9%; each line tells part of the story. This is based on 12 quarters of 4 measures. Why it matters: when the lines disagree, each line above matters more than any single label. ## How much does Gufic BioSciences earn on its capital? Gufic BioSciences Ltd earned a ROCE of 12% in FY26. Its return on capital used (ROIC) is 2.2 percentage points below its cost of capital, so growth here does not yet pay for the capital it uses. It comes from a 6.8% net margin and 0.70× asset turnover (sales divided by assets). Why the return is what it is (FY26): a 6.8% net margin × 0.70× asset turnover × 2.02× leverage (assets divided by equity) ≈ 9.6% on equity. The margin does its share; borrowing is a big part of it. The key test, return on capital used minus the cost of capital: 9.8% − 12.0% = −2.2 percentage points. The 12.0% is a standard assumption for the cost of capital in India, not an estimate for this company. Read the sign and size of the gap, not the decimals. Negative: growth at these returns loses value until returns improve. ## Does Gufic BioSciences have too much debt? Gufic BioSciences Ltd has total debt of ₹405 Cr against shareholder equity of ₹665 Cr as of Jun 2026, so its debt is 0.61× its equity. Year by year, that ratio went from 0.24 in FY22 to 0.61 in FY26. Keep that borrowing in mind when reading the returns on this page. ## What is the Gufic BioSciences shareholding pattern? No group of Gufic BioSciences Ltd's owners changed its stake by a full percentage point over the last two years. Foreign institutions moved +0.2 points over the same period, to 0.4%. This uses the four owner groups that companies report every quarter; nothing is guessed between filings. Over the last two years: Domestic institutions: +0.9 points over 8 quarters, to 3.4%; Foreign institutions: +0.2 points over 8 quarters, to 0.4%; Promoters: +0.0 points over 8 quarters, to 72.5%. ## How far is Gufic BioSciences from balance-sheet trouble? For Gufic BioSciences Ltd, the Z-score is not available, so we say so rather than guess one. It estimates how far the balance sheet is from trouble; it is not a forecast of failure. The debt, cash-flow and return sections show the balance-sheet figures we do have, each with its own date. ## How does Gufic BioSciences rank in its industry? 56.2 out of 100, rank 16 of 44 in Pharma - Formulators, with 71% of the evidence available. Gufic BioSciences Ltd scores 56.2 out of 100 against the 44 companies it is compared with in Pharma - Formulators, ranking 16. The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. The four parts add up to the total exactly: 23.7 + 11.1 + 9.8 + 11.6 = 56.2. This is the same number shown on the industry page; it is worked out once for the whole group and read here. What would change it: The score would fall if profit growth turns negative or margins stop improving while the share price lags its sector. ## Which companies is Gufic BioSciences compared with? Gufic BioSciences ranks 16 of 44 Pharma - Formulators companies on the 4-Factor Sector Score, with 56.2 out of 100. 1. [Rubicon Research Ltd](https://www.sectoralpha.in/stocks/rubicon-research-ltd) RUBICON · leader · Most evidence points up · 83% evidence 71.4 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 30.1/35 · Revenue 46.8% · Profit 91.4% · Operating margin change 2 points · 88% evidence Capital efficiency 18.6/25 · ROCE 28.4% · Operating margin 24% · 100% evidence Valuation 6.2/20 · P/E 92.5× · PEG 2.31 · 65% evidence Relative strength 16.5/20 · Lead over its industry 28.1% · Lead over NIFTY 500 53.6% · 1 year 160.5% · 70% evidence · 11 of 12 weeks ahead Exact sum: 30.1 + 18.6 + 6.2 + 16.5 = 71.4 · What this means: Earnings, capital efficiency and relative strength all agree. The open questions are about management, upcoming events and risks. 2. [Kwality Pharmaceuticals Ltd](https://www.sectoralpha.in/stocks/kwality-pharmaceuticals-ltd) KPL · breaking out · Most evidence points up · 81% evidence 71.4 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 29.9/35 · Revenue 37.9% · Profit 88.4% · Operating margin change 3 points · 88% evidence Capital efficiency 18.2/25 · ROCE 24.1% · Operating margin 25% · 100% evidence Valuation 11.0/20 · P/E 44.2× · PEG 0.54 · 100% evidence Relative strength 12.3/20 · Lead over its industry n/a · Lead over NIFTY 500 74.4% · 1 year 288.9% · 25% evidence · 9 of 9 weeks ahead Exact sum: 29.9 + 18.2 + 11 + 12.3 = 71.4 · What this means: Earnings, capital efficiency and relative strength all agree. The open questions are about management, upcoming events and risks. 3. [Accent Microcell Ltd](https://www.sectoralpha.in/stocks/accent-microcell-ltd) ACCENTMIC · leader · Most evidence points up · 65% evidence 70.5 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 21.4/35 · Revenue n/a · Profit n/a · Operating margin change 7 points · 27% evidence Capital efficiency 21.4/25 · ROCE 24.9% · Operating margin 24% · 100% evidence Valuation 9.1/20 · P/E 26.9× · PEG n/a · 50% evidence Relative strength 18.6/20 · Lead over its industry 21.4% · Lead over NIFTY 500 47.6% · 1 year 132.1% · 100% evidence · 12 of 12 weeks ahead Exact sum: 21.4 + 21.4 + 9.1 + 18.6 = 70.5 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 4. [Ajanta Pharma Ltd](https://www.sectoralpha.in/stocks/ajanta-pharma-ltd) AJANTPHARM · leader · Most evidence points up · 100% evidence 69.2 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 30.3/35 · Revenue 25% · Profit 29.8% · Operating margin change 7 points · 100% evidence Capital efficiency 21.3/25 · ROCE 34.5% · Operating margin 31% · 100% evidence Valuation 7.1/20 · P/E 34.7× · PEG 1.77 · 100% evidence Relative strength 10.5/20 · Lead over its industry -3.5% · Lead over NIFTY 500 20% · 1 year 42.3% · 100% evidence · 11 of 12 weeks ahead Exact sum: 30.3 + 21.3 + 7.1 + 10.5 = 69.2 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 5. [Glenmark Pharmaceuticals Ltd](https://www.sectoralpha.in/stocks/glenmark-pharmaceuticals-ltd) GLENMARK · breaking out · Most evidence points up · 86% evidence 69.2 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 29.1/35 · Revenue 32.9% · Profit 100% · Operating margin change 2 points · 88% evidence Capital efficiency 20.3/25 · ROCE 39.8% · Operating margin 20% · 100% evidence Valuation 11.2/20 · P/E 20.8× · PEG n/a · 50% evidence Relative strength 8.6/20 · Lead over its industry -11.4% · Lead over NIFTY 500 10.8% · 1 year 21.5% · 100% evidence · 9 of 12 weeks ahead Exact sum: 29.1 + 20.3 + 11.2 + 8.6 = 69.2 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 6. [Bliss GVS Pharma Ltd](https://www.sectoralpha.in/stocks/bliss-gvs-pharma-ltd) BLISSGVS · leader · Most evidence points up · 82% evidence 67.1 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 29.3/35 · Revenue 25% · Profit 43.1% · Operating margin change 8 points · 95% evidence Capital efficiency 14.7/25 · ROCE 16.9% · Operating margin 26% · 76% evidence Valuation 6.4/20 · P/E 42.4× · PEG n/a · 50% evidence Relative strength 16.7/20 · Lead over its industry 59% · Lead over NIFTY 500 86.2% · 1 year 312.8% · 100% evidence · 12 of 12 weeks ahead Exact sum: 29.3 + 14.7 + 6.4 + 16.7 = 67.1 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 7. [Fredun Pharmaceuticals Ltd](https://www.sectoralpha.in/stocks/fredun-pharmaceuticals-ltd) FREDUN · breaking out · Most evidence points up · 76% evidence 65.8 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 31.9/43.75 · Revenue 50.3% · Profit 91.3% · Operating margin change 0 points · 88% evidence Capital efficiency 19.0/31.25 · ROCE 21.5% · Operating margin 14% · 100% evidence Valuation 14.9/25 · P/E 52.7× · PEG 0.77 · 100% evidence Relative strength: no reading this week · its 20 points are shared across the other three Exact sum: 31.9 + 19 + 14.9 = 65.8 (no relative-strength reading this week; its 20 points are shared across the other three) · What this means: There is no relative-strength reading for this week, so the score is built from earnings, capital efficiency and valuation alone. 8. [Lupin Ltd](https://www.sectoralpha.in/stocks/lupin-ltd) LUPIN · quiet · Most evidence points up · 89% evidence 65.4 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 27.9/35 · Revenue 28.2% · Profit 49.2% · Operating margin change 2 points · 88% evidence Capital efficiency 19.4/25 · ROCE 29.9% · Operating margin 30% · 100% evidence Valuation 16.1/20 · P/E 15.4× · PEG 0.54 · 65% evidence Relative strength 2.0/20 · Lead over its industry -24.5% · Lead over NIFTY 500 -4.7% · 1 year 2.4% · 100% evidence · 0 of 12 weeks ahead Exact sum: 27.9 + 19.4 + 16.1 + 2 = 65.4 · What this means: Earnings are strong; relative strength in its sector is -24.5% and the one-year return is 2.4%. 9. [Ipca Laboratories Ltd](https://www.sectoralpha.in/stocks/ipca-laboratories-ltd) IPCALAB · turning · Most evidence points up · 78% evidence 65.4 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 24.0/35 · Revenue 10.6% · Profit 68% · Operating margin change 6 points · 83% evidence Capital efficiency 15.7/25 · ROCE 17% · Operating margin 24% · 76% evidence Valuation 11.0/20 · P/E 35.6× · PEG n/a · 50% evidence Relative strength 14.7/20 · Lead over its industry -0.5% · Lead over NIFTY 500 23.6% · 1 year 51.7% · 100% evidence · 10 of 12 weeks ahead Exact sum: 24 + 15.7 + 11 + 14.7 = 65.4 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 10. [Marksans Pharma Ltd](https://www.sectoralpha.in/stocks/marksans-pharma-ltd) MARKSANS · leader · Evidence leans up · 74% evidence 64.1 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 28.7/35 · Revenue 19.6% · Profit 48% · Operating margin change 9 points · 88% evidence Capital efficiency 17.2/25 · ROCE 18.8% · Operating margin 25% · 100% evidence Valuation 6.3/20 · P/E 26.8× · PEG 2.85 · 65% evidence Relative strength 11.9/20 · Lead over its industry n/a · Lead over NIFTY 500 40.1% · 1 year 68.4% · 25% evidence · 12 of 12 weeks ahead Exact sum: 28.7 + 17.2 + 6.3 + 11.9 = 64.1 · What this means: Earnings, capital efficiency and relative strength all agree. The open questions are about management, upcoming events and risks. 11. [FDC Ltd](https://www.sectoralpha.in/stocks/fdc-ltd) FDC · basing · Evidence leans up · 85% evidence 62.8 out of 100 Growth Capital Valuation Relative
12. [Corona Remedies Ltd](https://www.sectoralpha.in/stocks/corona-remedies-ltd) CORONA · turning · Evidence leans up · 73% evidence 62.5 out of 100 Growth Capital Valuation Relative
13. [Emcure Pharmaceuticals Ltd](https://www.sectoralpha.in/stocks/emcure-pharmaceuticals-ltd) EMCURE · losing its lead · Evidence leans up · 71% evidence 61.8 out of 100 Growth Capital Valuation Relative
14. [Mankind Pharma Ltd](https://www.sectoralpha.in/stocks/mankind-pharma-ltd) MANKIND · turning · Evidence leans up · 100% evidence 61.0 out of 100 Growth Capital Valuation Relative
15. [Zydus Lifesciences Ltd](https://www.sectoralpha.in/stocks/zydus-lifesciences-ltd) ZYDUSLIFE · leader · Evidence leans up · 96% evidence 58.1 out of 100 Growth Capital Valuation Relative
16. Gufic BioSciences Ltd this page GUFICBIO · leader · Evidence leans up · 71% evidence 56.2 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 23.7/35 · Revenue 16.6% · Profit 17.7% · Operating margin change 3 points · 88% evidence Capital efficiency 11.1/25 · ROCE 12.3% · Operating margin 18% · 100% evidence Valuation 9.8/20 · P/E 56.5× · PEG n/a · 50% evidence Relative strength 11.6/20 · Lead over its industry n/a · Lead over NIFTY 500 23.6% · 1 year 26.7% · 25% evidence · 12 of 12 weeks ahead Exact sum: 23.7 + 11.1 + 9.8 + 11.6 = 56.2 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 17. [ERIS Lifesciences Ltd](https://www.sectoralpha.in/stocks/eris-lifesciences-ltd) ERIS · basing · Evidence leans up · 67% evidence 56.1 out of 100 Growth Capital Valuation Relative
18. [Strides Pharma Science Ltd](https://www.sectoralpha.in/stocks/strides-pharma-science-ltd) STAR · breaking out · Evidence leans up · 75% evidence 55.3 out of 100 Growth Capital Valuation Relative
19. [Caplin Point Laboratories Ltd](https://www.sectoralpha.in/stocks/caplin-point-laboratories-ltd) CAPLIPOINT · losing its lead · Evidence leans up · 96% evidence 54.3 out of 100 Growth Capital Valuation Relative
20. [Wockhardt Ltd](https://www.sectoralpha.in/stocks/wockhardt-ltd) WOCKPHARMA · losing its lead · Evidence leans up · 71% evidence 52.8 out of 100 Growth Capital Valuation Relative
21. [Kilitch Drugs (India) Ltd](https://www.sectoralpha.in/stocks/kilitch-drugs-indialtd) KILITCH · breaking out · Evidence leans up · 78% evidence 51.3 out of 100 Growth Capital Valuation Relative
22. [Akums Drugs & Pharmaceuticals Ltd](https://www.sectoralpha.in/stocks/akums-drugs-pharmaceuticals-ltd) AKUMS · leader · Evidence leans up · 71% evidence 50.9 out of 100 Growth Capital Valuation Relative
23. [Alkem Laboratories Ltd](https://www.sectoralpha.in/stocks/alkem-laboratories-ltd) ALKEM · quiet · Evidence leans down · 78% evidence 47.6 out of 100 Growth Capital Valuation Relative
24. [Alembic Pharmaceuticals Ltd](https://www.sectoralpha.in/stocks/alembic-pharmaceuticals-ltd) APLLTD · turning · Evidence leans down · 81% evidence 46.9 out of 100 Growth Capital Valuation Relative
25. [Bajaj Healthcare Ltd](https://www.sectoralpha.in/stocks/bajaj-healthcare-ltd) BAJAJHCARE · quiet · Evidence leans down · 100% evidence 46.5 out of 100 Growth Capital Valuation Relative
26. [Lincoln Pharmaceuticals Ltd](https://www.sectoralpha.in/stocks/lincoln-pharmaceuticals-ltd) LINCOLN · quiet · Evidence leans down · 100% evidence 46.0 out of 100 Growth Capital Valuation Relative
27. [Bharat Parenterals Ltd](https://www.sectoralpha.in/stocks/bharat-parenterals-ltd) BPLPHARMA · breaking out · Too little evidence to rank firmly · 52% evidence 45.9 out of 100 Growth Capital Valuation Relative
28. [Aurobindo Pharma Ltd](https://www.sectoralpha.in/stocks/aurobindo-pharma-ltd) AUROPHARMA · leader · Evidence leans down · 96% evidence 45.7 out of 100 Growth Capital Valuation Relative
29. [Amrutanjan Health Care Ltd](https://www.sectoralpha.in/stocks/amrutanjan-health-care-ltd) AMRUTANJAN · turning · Evidence leans down · 96% evidence 44.9 out of 100 Growth Capital Valuation Relative
30. [RPG Life Sciences Ltd](https://www.sectoralpha.in/stocks/rpg-life-sciences-ltd) RPGLIFE · losing its lead · Evidence leans down · 100% evidence 43.1 out of 100 Growth Capital Valuation Relative
31. [J B Chemicals & Pharmaceuticals Ltd](https://www.sectoralpha.in/stocks/j-b-chemicals-pharmaceuticals-ltd) JBCHEPHARM · Too little evidence to rank firmly · 59% evidence 42.6 out of 100 Growth Capital Valuation Relative
32. [Zim Laboratories Ltd](https://www.sectoralpha.in/stocks/zim-laboratories-ltd) ZIMLAB · leader · Evidence leans down · 71% evidence 42.2 out of 100 Growth Capital Valuation Relative
33. [Sun Pharmaceutical Industries Ltd](https://www.sectoralpha.in/stocks/sun-pharmaceutical-industries-ltd) SUNPHARMA · quiet · Evidence leans down · 100% evidence 39.4 out of 100 Growth Capital Valuation Relative
34. [Dr Reddys Laboratories Ltd](https://www.sectoralpha.in/stocks/dr-reddys-laboratories-ltd) DRREDDY · turning · Evidence leans down · 100% evidence 39.4 out of 100 Growth Capital Valuation Relative
35. [Natco Pharma Ltd](https://www.sectoralpha.in/stocks/natco-pharma-ltd) NATCOPHARM · quiet · Evidence leans down · 96% evidence 38.8 out of 100 Growth Capital Valuation Relative
36. [Bafna Pharmaceuticals Ltd](https://www.sectoralpha.in/stocks/bafna-pharmaceuticals-ltd) BAFNAPH · breaking out · Evidence leans down · 74% evidence 35.8 out of 100 Growth Capital Valuation Relative
37. [Cipla Ltd](https://www.sectoralpha.in/stocks/cipla-ltd) CIPLA · turning · Evidence leans down · 100% evidence 35.4 out of 100 Growth Capital Valuation Relative
38. [Torrent Pharmaceuticals Ltd](https://www.sectoralpha.in/stocks/torrent-pharmaceuticals-ltd) TORNTPHARM · losing its lead · Most evidence points down · 100% evidence 34.6 out of 100 Growth Capital Valuation Relative
39. [Biocon Ltd](https://www.sectoralpha.in/stocks/biocon-ltd) BIOCON · quiet · Most evidence points down · 96% evidence 34.4 out of 100 Growth Capital Valuation Relative
40. [Suven Life Sciences Ltd](https://www.sectoralpha.in/stocks/suven-life-sciences-ltd) SUVEN · quiet · Most evidence points down · 64% evidence 33.1 out of 100 Growth Capital Valuation Relative
41. [Influx Healthtech Ltd](https://www.sectoralpha.in/stocks/influx-healthtech-ltd) INFLUX · quiet · Too little evidence to rank firmly · 42% evidence 49.7 out of 100 Growth Capital Valuation Relative
42. [Syncom Healthcare Ltd](https://www.sectoralpha.in/stocks/syncom-healthcare-ltd) SYNCOM · Too little evidence to rank firmly · 17% evidence 42.3 out of 100 Growth Capital Valuation Relative
43. [Indoco Remedies Ltd](https://www.sectoralpha.in/stocks/indoco-remedies-ltd) INDOCO · losing its lead · Too little evidence to rank firmly · 49% evidence 38.4 out of 100 Growth Capital Valuation Relative
44. [Sai Parenterals Ltd](https://www.sectoralpha.in/stocks/sai-parenterals-ltd) SAIPARENT · turning · Too little evidence to rank firmly · 31% evidence 36.7 out of 100 Growth Capital Valuation Relative

Missing figures are not scored as bad. They lower the confidence and pull the final score toward the middle. Relative strength counts only when the company has a reading for this week; with no reading, that factor is left out and its 20 points are shared across the other three in proportion. PEG is not shown when the ratio cannot mean anything: the company must be making a profit, its price-to-earnings must be positive, and its three-year earnings growth must fall between 5% and 60%. Dividing a price multiple by a loss, or by growth measured off a tiny base, produces a number that looks precise and tells you nothing. Under relative strength, one mark per week shows the last 12 weeks: a mark is filled where the company led NIFTY 500 by 5% or more over the 13 weeks ending that week, which is the same test used everywhere on this site. Price stage places the company on the same six-step path the industry is placed on (basing, turning, breaking out, leader, fading, asleep), read from how many weeks running it has led NIFTY 500 and whether that lead is growing or shrinking. It describes where the share price stands, not the direction of earnings, and it is not a recommendation; it is left blank for a company whose weekly history is too short or too stale to read. The figures in this ranking come from the industry comparison: results through the Sep 2026 quarter, and the P/E at that quarter's end. The sections above use the latest weekly price, so a P/E or return there can differ a little from the one here. The stage words in this ranking (such as losing its lead or breaking out) describe the lead over the index, not the price phase in the price section. Related companies: [Pharma - Formulators](https://www.sectoralpha.in/sectors/pharma-formulators), all 44 compared on one page. ## Which companies are close to Gufic BioSciences in size? Gufic BioSciences is the 30th largest of 44 Pharma - Formulators companies on Sector Alpha by market value (scores of 30 October 2026). Just above it: Bliss GVS Pharma, FDC and RPG Life Sciences. Just below it: Kwality Pharmaceuticals, Fredun Pharmaceuticals and Sai Parenterals. ### Pharma - Formulators companies close in size

1. [Bliss GVS Pharma Ltd](https://www.sectoralpha.in/stocks/bliss-gvs-pharma-ltd) ₹6,888 crore
2. [FDC Ltd](https://www.sectoralpha.in/stocks/fdc-ltd) ₹6,138 crore
3. [RPG Life Sciences Ltd](https://www.sectoralpha.in/stocks/rpg-life-sciences-ltd) ₹4,260 crore
4. Gufic BioSciences Ltd ₹4,147 crore
5. [Kwality Pharmaceuticals Ltd](https://www.sectoralpha.in/stocks/kwality-pharmaceuticals-ltd) ₹3,606 crore
6. [Fredun Pharmaceuticals Ltd](https://www.sectoralpha.in/stocks/fredun-pharmaceuticals-ltd) ₹2,341 crore
7. [Sai Parenterals Ltd](https://www.sectoralpha.in/stocks/sai-parenterals-ltd) ₹2,306 crore

[All 44 Pharma - Formulators companies, largest first](https://www.sectoralpha.in/sectors/pharma-formulators#all-companies)

### Companies close in size in other industries

1. [ICRA Ltd](https://www.sectoralpha.in/stocks/icra-ltd) ₹4,151 crore · Credit Rating Agencies
2. [AGI Greenpac Ltd](https://www.sectoralpha.in/stocks/agi-greenpac-ltd) ₹4,148 crore · Packaging - FMCG/Consumers
3. Gufic BioSciences Ltd ₹4,147 crore
4. [Venus Pipes & Tubes Ltd](https://www.sectoralpha.in/stocks/venus-pipes-tubes-ltd) ₹4,147 crore · Steel - Tubes/Pipes
5. [SEAMEC Ltd](https://www.sectoralpha.in/stocks/seamec-ltd) ₹4,134 crore · Shipping

## What else do people ask about Gufic BioSciences? ### What is Gufic BioSciences's share price today? Gufic BioSciences Ltd's share price is ₹416.50, +28.0% over the past year. The whole company is worth ₹4,172 Cr on the market. In the last 52 weeks it traded between ₹279 to ₹445; today it is 83% of the way up from the low, 10.4% above its 200-day average (as of 3 November 2026). ### What were Gufic BioSciences's latest quarterly results? Gufic BioSciences Ltd reported revenue of ₹261 Cr and net profit of ₹22.0 Cr for the Jun 2026 quarter. Revenue rose 16.5% and profit rose 69.2% compared with a year earlier. Earnings per share were ₹2.22. The operating margin was 18.0%, 3.0 percentage points higher than a year earlier (as of 3 November 2026). ### What is Gufic BioSciences's market cap? Gufic BioSciences Ltd's market capitalisation is ₹4,172 Cr at a share price of ₹416.50. Market cap is the share price times the number of shares, so it changes whenever the price moves (as of 3 November 2026). ### How is Gufic BioSciences performing? Gufic BioSciences Ltd's share price has been rising for 18 weeks. In its latest quarter, revenue rose 16.5% and profit rose 69.2% compared with a year earlier. Over the past 13 weeks it has done better than the NIFTY 500, for 31 weeks running (as of 3 November 2026). ### Will Gufic BioSciences's share price go up? This page does not forecast Gufic BioSciences Ltd's share price. What it shows instead: the share price is ₹416.50, and it has been rising for 18 weeks. Its P/E of 56.8× is higher than 63% of its own last 2 years (as of 3 November 2026). ### Who owns Gufic BioSciences? Promoters own 72.5% of Gufic BioSciences Ltd, foreign institutions 0.4%, domestic institutions 3.4% and the public 23.7% (latest quarter). No group of owners changed its stake by a full point over the last two years (as of 3 November 2026). ### Where is Gufic BioSciences in its business cycle? Gufic BioSciences Ltd's FY26 operating margin was 16.0%, against a 3-year range of 16.0% to 19.0%: the low end of its own range, which is often where recoveries start. The latest quarter was 18.0%. Comparing margins with a company's own long history is a good way to see where it is in its cycle (as of 3 November 2026). ### What could break the Gufic BioSciences story? The main question: the share price moved +28.0% in a year while yearly earnings per share moved −7.9%. The difference came from the market paying a higher multiple. On price, this page treats a rise as over when the share price closes below its 200-day average on two Fridays in a row (as of 3 November 2026). ### Is Gufic BioSciences a stock worth studying right now? What the numbers show: Gufic BioSciences Ltd's share price, valuation and earnings point in different directions. The next one or two quarters should make it clearer. The main open question: whether earnings grow into a price that has already moved. Every number on this page is worked out by code from the published figures, with no forecasts and no price opinions (as of 3 November 2026). ### Is there a Gufic BioSciences share price forecast for 2026? What management itself guided: Company growth of 15-20% on a year earlier for FY27; 15% described as the bare minimum. ## Lists

- Momentum stocks: https://www.sectoralpha.in/momentum-stocks-india
- Pharma stocks: https://www.sectoralpha.in/sectors/pharma-stocks-india

This is research, not advice. We’re not SEBI-registered.